scholarly journals Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Tablets

2013 ◽  
Vol 48 (1) ◽  
pp. 48-56 ◽  
Author(s):  
Dennis J. Cada ◽  
Silvia Torres ◽  
Terri L. Levien ◽  
Danial E. Baker
Keyword(s):  
Information Exchange ◽  
Hospital Pharmacy ◽  
Drug Class ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Target Drug ◽  
Omacetaxine Mepesuccinate ◽  
On Line ◽  
Sodium Picosulfate

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The January 2013 monograph topics are onperampanel, omacetaxine mepesuccinate, ocriplasmin, sodium picosulfate/magnesium oxide/anhydrous citric acid, and lomitapide. The DUE/MUE is on perampanel.

Fidaxomicin

2011 ◽  
Vol 46 (11) ◽  
pp. 884-890
Author(s):  
J. Cada Dennis ◽  
L. Levien Terri ◽  
E. Baker Danial
Keyword(s):  
Drug Utilization ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Medication Use ◽  
Bulletin Board ◽  
Phase 3 ◽  
Target Drug ◽  
On Line ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800–322–4349. The November 2011 monograph topics are on indacaterol, brentuximub vedotin, icatibant injection, aflibercept, and centruroides (Scorpion) immune F(ab′)2. The DUE/MUE is on indacaterol.

Ticagrelor

2012 ◽  
Vol 47 (1) ◽  
pp. 47-56
Author(s):  
J. Cada Dennis ◽  
Terri L. Levien ◽  
E. Baker Danial
Keyword(s):  
Drug Utilization ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Medication Use ◽  
Bulletin Board ◽  
Phase 3 ◽  
Target Drug ◽  
On Line ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The January 2012 monograph topics are on clobazam, ruxolitinib, bupivacaine liposome injection suspension, ivacaftor, and teriflunomide. The DUE/MUE is on clobazam.

Granisetron Transdermal System

2009 ◽  
Vol 44 (4) ◽  
pp. 332-339 ◽  
Author(s):  
Dennis J. Cada ◽  
Terri L. Levien ◽  
Danial E. Baker
Keyword(s):  
Drug Utilization ◽  
Proton Pump ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Fibrinogen Concentrate ◽  
Phase 3 ◽  
Target Drug ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The April 2009 monograph topics are dexlansoprazole, milnacipran, oxybutynin chloride 10% gel, fibrinogen concentrate (human), and ecallantide injection. The DUE is on proton pump inhibitors.

Micafungin Sodium

2005 ◽  
Vol 40 (8) ◽  
pp. 693-704
Author(s):  
Dennis J. Cada ◽  
Terri Levien ◽  
Danial E. Baker
Keyword(s):  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Pharmacy And Therapeutics Committee ◽  
Cd Rom ◽  
Target Drug ◽  
Pulmonary Arterial ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The August 2005 monograph topics are sildenafil citrate for pulmonary arterial hypertension, paracalcitol capsules, galsulfase, dalbavancin, and febuxostat. The DUE is on paricalcitol capsules.

Exenatide Injection

2005 ◽  
Vol 40 (11) ◽  
pp. 994-1003
Author(s):  
Dennis J. Cada ◽  
Terri Levien ◽  
Danial E. Baker
Keyword(s):  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Pharmacy And Therapeutics Committee ◽  
Cd Rom ◽  
Target Drug ◽  
Drug Utilization Evaluation ◽  
Ophthalmic Suspension

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The November 2005 monograph topics are pregabalin, nepafenac ophthalmic suspension, mecasermin (rDNA origin) injection, abatacept, and rimonabant. The DUE is on pregabalin.

Rotigotine Transdermal System

2007 ◽  
Vol 42 (10) ◽  
pp. 939-950 ◽  
Author(s):  
Dennis J. Cada ◽  
Terri Levien ◽  
Danial E. Baker
Keyword(s):  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Pharmacy And Therapeutics Committee ◽  
Cd Rom ◽  
Target Drug ◽  
Rotigotine Transdermal System ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD-ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The October 2007 monograph topics are maraviroc, etravirine, bifeprunox, regadenoson, and fesoterodine. The DUE is on maraviroc.

Clevidipine Butyrate Injectable Emulsion

2008 ◽  
Vol 43 (11) ◽  
pp. 903-912 ◽  
Author(s):  
Dennis J. Cada ◽  
Terri L. Levien ◽  
Danial E. Baker
Keyword(s):  
Drug Utilization ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Target Drug ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The November 2008 monograph topics are on romiplostim, rivaroxaban, golimumab, dronedarone, and degarelix. The DUE is on romiplostim.

Entecavir

2005 ◽  
Vol 40 (9) ◽  
pp. 798-811
Author(s):  
Dennis J. Cada ◽  
Terri Levien ◽  
Danial E. Baker
Keyword(s):  
Information Exchange ◽  
Hospital Pharmacy ◽  
Insulin Detemir ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Cd Rom ◽  
Target Drug ◽  
Hydralazine Hydrochloride ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The September 2005 monograph topics are tigecycline, insulin detemir injection, tipranavir, isosorbide dinitrate/hydralazine hydrochloride, and muraglitazar. The DUE is on paricalcitol tigecycline.

Febuxostat

2009 ◽  
Vol 44 (8) ◽  
pp. 688-699
Author(s):  
Dennis J. Cada ◽  
Terri L. Levien ◽  
Danial E. Baker
Keyword(s):  
Drug Utilization ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Target Drug ◽  
Drug Utilization Evaluation ◽  
Ophthalmic Suspension

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The August 2009 monograph topics are tolvaptan, besifloxacin ophthalmic suspension 0.6%, tadalafil, bromocriptine mesylate, and acetaminophen intravenous. The DUE is on tolvaptan.

Alvimopan

2008 ◽  
Vol 43 (10) ◽  
pp. 819-829
Author(s):  
Dennis J. Cada ◽  
Terri L. Levien ◽  
Danial E. Baker
Keyword(s):  
Drug Utilization ◽  
Tenofovir Disoproxil Fumarate ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Target Drug ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and are also available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The FIX., call The Formulary at 800-322-4349. The October 2008 monograph topics are on clevidipine butyrate injectable emulsion, tetrabenazine, tenofovir disoproxil fumarate tablets, ferumoxytol, and saxagliptin. The DUE is on clevidipine butyrate injectable emulsion.

Sign in / Sign up

Export Citation Format

Share Document